Navigation Links
Life Sciences Venture Capital Funding Drops 14% During 2012, According To The MoneyTree Report
Date:2/7/2013

NEW YORK, Feb. 7, 2013 /PRNewswire/ -- US venture capital (VC) funding in the life sciences sector, which includes the Biotechnology and Medical Device industries, dropped 14 percent in dollars and 7 percent in deals during 2012 according to a new PwC US report, "Double-digit dip" that includes data from the MoneyTree™ Report from PricewaterhouseCoopers LLP and the National Venture Capital Association based on data provided by Thomson Reuters.  Venture capitalists invested a total of $6.6 billion in 779 Life Sciences deals during the year, compared with $7.7 billion in 836 deals during 2011. The number of Life Sciences companies receiving VC funding for the first time reached the lowest level since 1995 with only 135 companies receiving funding in 2012.

(Logo: http://photos.prnewswire.com/prnh/20100917/NY66894LOGO )

Compared to the prior quarter, Life Sciences venture funding rose 11 percent in Q4 2012 to $1.9 billion. Deal volume also increased, rising 12 percent to 187 deals compared to the prior quarter.

For all sectors, VCs invested $26.5 billion in 3,698 deals in 2012, a 10 percent drop in dollars and 6 percent decline in deals from the prior year. Venture investors funneled $26.5 billion into 3,698 deals during 2012. While total investments saw a decline for the year, Deal volume in Q4 2012 rose 5 percent compared to the prior quarter.  However, dollars invested did decline 3 percent over the same time period to $6.4 billion in 968 deals.

"The 2012 investment levels came in lower than what we saw during 2011," said Tracy T. Lefteroff , global managing partner of the venture capital practice at PwC US. "The pickup during the third quarter for Biotechnology and for both industries during the fourth quarter wasn't enough to outpace lower funding levels during the first half of 2012. Global
'/>"/>

SOURCE PwC US
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
2. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
3. BioDelivery Sciences to Present at the 15th Annual BIO CEO and Investor Conference
4. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
5. InternetArray Collaborates with Health Sciences Group to Fund Medical Marijuana Social Media/Mobile Apps Development
6. US Patent Granted to RBC Life Sciences for Supplement that Supports Cognitive Function
7. Emmaus Life Sciences Issues Statement in Response to Announcement by AFH Holding & Advisory
8. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
9. IntelliCell BioSciences Receives Notice of Allowance for its US Patent for "Ultrasonic Cavitation of Adipose Tissue to Produce Stromal Vascular Fraction Regenerative Cells"
10. BioDelivery Sciences Announces Completion of BNX Safety Study
11. Government Hospitals in Ecuador Continue to Invest in Integrity Life Sciences Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014  Beamz Interactive, Inc. (OTCQB: BZIC), a ... announced that it has signed an agreement with ... of innovative prosthetic, orthotic and assistive technology products ... agreement, RSL Steeper will promote and supply the ... use within UK residential care facilities through its ...
(Date:12/17/2014)... 17, 2014  ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE ... Trademark Office (USPTO) has issued a key patent ... immunotherapeutic vaccine targeting six tumor antigens that are ... Patent No. 8,871,211, which issued October 28, 2014, ... a dendritic cell composition comprising peptide epitopes of ...
(Date:12/17/2014)... MARLBOROUGH, Mass. , Dec. 17, 2014 /PRNewswire/ ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today announced completion of enrollment in ... results from the 3-month observations confirmed the 1-month ... year:  Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... YORK, March 31, 2011 Intercept Pharmaceuticals, Inc., today ... double-blind  Phase II clinical trial of obeticholic acid (OCA) ... (PBC).  The study evaluated the effects of 10 mg ... patients with elevated alkaline phosphatase (AP).  AP is a ...
... Services Corp., a leading provider of pharmaceutical product ... of Dean Shirazi, Ph.D., to Vice President, Analytical ... 4, 2011. (Logo:   https://photos.prnewswire.com/prnh/20110330/CG74146LOGO ) ... in June 1992 as a Senior Scientist, has ...
Cached Medicine Technology:Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis 2Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis 3AAIPharma Services Announces Promotion of Dean Shirazi 2
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, 2014 (HealthDay ... work commitment is a big reason why, new research suggests. ... Mathias Basner, an assistant professor of sleep and chronobiology in ... A time-use survey of nearly 125,000 Americans, ages 15 ... exchanged for sleep. Short sleepers -- those who slept six ...
(Date:12/15/2014)... Street Dental Team ( http://www.MainStreetDentalTeam.com ), Unionville’s first full-time ... providing evidence on the impact of 100% pure fruit ... enough evidence already exists showing a negative link between ... the onset of tooth decay. One question that has ... fruit juice, meaning it is completely natural with no ...
(Date:12/15/2014)... Health Dialog, a leading provider ... it has received Patient Oriented Accreditation from the ... Disease Management (DM) Programs for asthma, congestive heart ... disease and diabetes. This marks the 12th continuous ... Disease Management (DM) Programs, reaffirming Health Dialog’s focus ...
(Date:12/15/2014)... 15, 2014 Kathy McAfee, America's Marketing ... World Awards in the category of Best Blog 2014. ... for her weekly career blog Networking Ahead ... help professionals elevate their talent and influence through better ... after her book Networking Ahead for Business, has been ...
(Date:12/15/2014)... Ontario (PRWEB) December 15, 2014 Bacteroides is ... Not only is it much more prevalent than coliforms, it ... replicate in the environment. , Key Benefits of the ... for fecal contamination , Eliminates false positives from ... Specificity and Sensitivity , Maintain the same ...
Breaking Medicine News(10 mins):Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Kathy McAfee, America’s Marketing Motivator, Wins Best Blog from Women World Awards 2
... N.C., Feb. 5 Many leading companies have ... various reasons, but in times of economic adversity, ... functions within companies are being questioned. Although internal ... purpose, these organizations often grow and take on ...
... Republic of The Gambia has decided to create a ... (Iniciaci sense mutilaci), directed by UAB researcher Adriana Kaplan, ... Institute of Primary Care Research IDIAP Jordi Gol and ... eliminate the genital lesions created by these traditional rituals ...
... (CMC) has,selected Surgical Information Systems (SIS) to be ... in Scranton, PA. , ... CMC chose the SIS Solution ... and operational efficiencies in the surgery department.,In addition ...
... Minutes Without Side Effects or PillsPHOENIX and SCOTTSDALE, ... specialist Morton I. Hyson, M.D., will announce a ... according to Clinical Topicals PHP. The treatment works ... or contraindications ( www.HysonHeadache.com ). After a decade ...
... preventing cystic fibrosis lung disease in an animal model by ... the first therapy to successfully attack the root cause of ... mice are given inhalation treatment with the drug in the ... lungs and airway inflammation and chronic lung damage can be ...
... Barcode Point-of-Care Patient Safety Solution-SAN DIEGO, Feb. 5 ... barcode point-of-care (BPOC) solutions to hospitals, today announced ... is now being used by 55 U.S. hospitals. ... to go live with the IntelliDOT System on January ...
Cached Medicine News:Health News:New Study Provides Benchmarks for Best Practices for Valuing Internal Consulting Organizations 2Health News:Gambia takes on as National Program UAB project to abolish FGM 2Health News:Gambia takes on as National Program UAB project to abolish FGM 3Health News:Community Medical Center (Scranton) Selects SIS Perioperative Solution 2Health News:Neurologist to Announce Breakthrough Headache Treatment 2Health News:Hope for preventative treatment for cystic fibrosis lung disease 2Health News:Hope for preventative treatment for cystic fibrosis lung disease 3Health News:IntelliDOT Bedside Medication Administration(TM) Goes Live at 55th Hospital 2Health News:IntelliDOT Bedside Medication Administration(TM) Goes Live at 55th Hospital 3Health News:IntelliDOT Bedside Medication Administration(TM) Goes Live at 55th Hospital 4
10% Casein digest (NZ amine), 5.0% Sodium Chloride, 5.0% Yeast Extract....
0.5% Yeast Extract, 2.0% Tryp, 10mM Sodium Chloride, 2.5mM Potassium Chloride....
S.O.C. Medium...
... rHead Radial Implant System provides todays ... to radial head replacement. Modular ... patient anatomy while minimizing ligamentous and ... designed alignment guide assists in both ...
Medicine Products: